Featured news

The Annual Report for 2024 is now available Annual Report 2024 Nanologica AB (publ)

FINANCIAL SUMMARY • Net sales for the fourth quarter amounted to SEK 6,715 thousand (75) and for the full year to SEK 14,538 thousand (1,443) • Operating loss for the quarter amounted to SEK -11,890 thousand (-35,638) and for the full year to SEK -59,255 thousand (-69,963). For the full year, operating profit was affected by write-downs of tangible and intangible assets totaling SEK 10,434 thousand (14,523). • Loss after tax for the quarter amounted

Nanologica has received yet another order for the company’s silica-based purification media NLAB Saga® from the Chinese pharmaceutical manufacturer Chengdu Shengnuo Biopharm Co. (“Shengnuo”).  The order is worth approximately SEK 8.5 million and the customer uses Nanologica’s purification media in the production of a GLP-1 analogue.  Since June 2024, Shengnuo has placed five orders of NLAB Saga® with a total value of approximately SEK 18 million. ”The Chinese market is very interesting for us and

Nanaologica Receives Order on NLAB Saga® Valued at approx. SEK 1,9 Million from Returning Customer in China Nanologica has received another order for the company’s silica-based purification media NLAB Saga® from a returning customer in China. This is the fourth order since June from this customer who uses NLAB Saga® in the production of a GLP-1 analogue. “The fact that this customer is now placing another order for NLAB Saga® confirms once again that our